Becaplermin rhPDGF

Becaplermin rhPDGF Brand Name– Regranex

What is Becaplermin rhPDGF

Becaplermin rhPDGF BB is approved for use as a topical wound healing agent to treat lower extremity, neuropathic, diabetic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply.

The efficacy of becaplermin has not been established for diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue, for diabetic ischemic ulcers, for venous stasis ulcers, or for pressure ulcers.

The drug is a recombinant formulation of human platelet-derived growth factor (PDGF). Becaplermin is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds and is produced by insertion of the gene for the B chain of PDGF into the yeast, 

Saccharomyces cerevisiae. Platelet-derived growth factor is a protein that is normally secreted by platelets, macrophages, endothelial cells, and, in some cases, fibroblasts.

Indications

  • decubitus ulcer
  • diabetic foot ulcer
  • wound management

For the treatment of lower extremity diabetic neuropathic ulcers (e.g., diabetic foot ulcer) that extend into the subcutaneous tissue or beyond and have an adequate blood supply

Side Effects

  1. erythema
  2. new primary malignancy
  3. rash

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • breast-feeding
  • children
  • corticosteroid therapy
  • infants
  • infection
  • mortality
  • neonates
  • neoplastic disease
  • new primary malignancy
  • peripheral vascular disease
  • pregnancy

Interactions

There are no drug interactions associated with Becaplermin, rh-PDGF products.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top